6eaq - Revision history

OCA at 06:21, 11 October 2023

OCA — Wed, 11 Oct 2023 06:21:54 GMT

←Older revision		Revision as of 06:21, 11 October 2023
Line 3:		Line 3:
	<StructureSection load='6eaq' size='340' side='right'caption='[[6eaq]], [[Resolution\|resolution]] 2.22Å' scene=''>		<StructureSection load='6eaq' size='340' side='right'caption='[[6eaq]], [[Resolution\|resolution]] 2.22Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6eaq]] is a 3 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EAQ OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6EAQ FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6eaq]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EAQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6EAQ FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>~~</td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.22Å</td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">FCGR3B, CD16B, FCG3, FCGR3, IGFR3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6eaq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6eaq OCA], [~~http~~://pdbe.org/6eaq PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6eaq RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6eaq PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6eaq ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6eaq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6eaq OCA], [https://pdbe.org/6eaq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6eaq RCSB], [https://www.ebi.ac.uk/pdbsum/6eaq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6eaq ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/IGG1_HUMAN IGG1_HUMAN]] Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref> [[http://www.uniprot.org/uniprot/FCG3B_HUMAN FCG3B_HUMAN]] Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.	+	[https://www.uniprot.org/uniprot/IGG1_HUMAN IGG1_HUMAN] Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 23:		Line 23:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Barb~~, A W~~]]	+	[[Category: Barb AW]]
-	[[Category: Roberts~~, J T]]~~	+	[[Category: Roberts JT]]
-	~~[[Category: Cd16b]]~~	+
-	~~[[Category: Fcgr3b]]~~	+
-	~~[[Category: Glycoprotein]]~~	+
-	~~[[Category: Glycosylation]]~~	+
-	~~[[Category: Igg1 fc]]~~	+
-	~~[[Category: Immune system~~]]	+

OCA at 10:13, 4 December 2019

OCA — Wed, 04 Dec 2019 10:13:27 GMT

←Older revision		Revision as of 10:13, 4 December 2019
Line 1:		Line 1:

	==Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc==		==Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc==
-	<StructureSection load='6eaq' size='340' side='right' caption='[[6eaq]], [[Resolution\|resolution]] 2.22Å' scene=''>	+	<StructureSection load='6eaq' size='340' side='right'caption='[[6eaq]], [[Resolution\|resolution]] 2.22Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[6eaq]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EAQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6EAQ FirstGlance]. <br>		<table><tr><td colspan='2'>[[6eaq]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EAQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6EAQ FirstGlance]. <br>
Line 24:		Line 24:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Barb, A W]]		[[Category: Barb, A W]]
	[[Category: Roberts, J T]]		[[Category: Roberts, J T]]

OCA at 08:59, 14 November 2018

OCA — Wed, 14 Nov 2018 08:59:21 GMT

←Older revision		Revision as of 08:59, 14 November 2018
Line 3:		Line 3:
	<StructureSection load='6eaq' size='340' side='right' caption='[[6eaq]], [[Resolution\|resolution]] 2.22Å' scene=''>		<StructureSection load='6eaq' size='340' side='right' caption='[[6eaq]], [[Resolution\|resolution]] 2.22Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6eaq]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EAQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6EAQ FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6eaq]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EAQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6EAQ FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">FCGR3B, CD16B, FCG3, FCGR3, IGFR3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6eaq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6eaq OCA], [http://pdbe.org/6eaq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6eaq RCSB], [http://www.ebi.ac.uk/pdbsum/6eaq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6eaq ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6eaq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6eaq OCA], [http://pdbe.org/6eaq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6eaq RCSB], [http://www.ebi.ac.uk/pdbsum/6eaq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6eaq ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/IGG1_HUMAN IGG1_HUMAN]] Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref> [[http://www.uniprot.org/uniprot/FCG3B_HUMAN FCG3B_HUMAN]] Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.		[[http://www.uniprot.org/uniprot/IGG1_HUMAN IGG1_HUMAN]] Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref> [[http://www.uniprot.org/uniprot/FCG3B_HUMAN FCG3B_HUMAN]] Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Therapeutic mAbs engage Fc gamma receptor III (CD16) to elicit a protective cell-mediated response and destroy the target tissue. Newer drugs designed to bind CD16a with increased affinity surprisingly also elicit protective CD16b-mediated responses. However, it is unclear why immunoglobulin G (IgG) binds CD16a with more than 10-fold higher affinity than CD16b even though these receptors share > 97% identity. Here, we identified one residue, Gly129, that contributes to the greater IgG-binding affinity of CD16a. The CD16b variant D129G bound IgG1 Fc with two-fold higher affinity than CD16a and with 90-fold higher affinity than WT. Conversely, the binding affinity of CD16a-G129D was decreased 128-fold relative to WT CD16a and comparably to that of WT CD16b. The interaction of IgG1 Fc with CD16a, but not with CD16b, is known to be sensitive to the composition of the asparagine-linked carbohydrates (N-glycans) attached to the receptor. CD16a and CD16b-D129G displaying minimally processed oligomannose N-glycans bound to IgG1 Fc with about 5.2-fold increased affinity compared with variants with highly processed complex-type N-glycans. CD16b and the CD16a-G129D variant exhibited a smaller 1.9-fold affinity increase with oligomannose N-glycans. A model of glycosylated CD16b bound to IgG1 Fc determined to 2.2 A resolution combined with a 250-ns all-atom molecular dynamics simulation showed that the larger Asp129 residue deformed the Fc-binding surface. These results reveal how Asp-129 in CD16b affects its binding affinity for IgG1 Fc and suggest that antibodies engineered to engage CD16b with high affinity must accommodate the Asp-129 sidechain.
		+
		+	A single amino acid distorts the Fc gamma receptor IIIb / CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.,Roberts JT, Barb AW J Biol Chem. 2018 Oct 25. pii: RA118.005273. doi: 10.1074/jbc.RA118.005273. PMID:30361439<ref>PMID:30361439</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6eaq" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Barb, A W]]		[[Category: Barb, A W]]
	[[Category: Roberts, J T]]		[[Category: Roberts, J T]]

OCA at 12:15, 7 November 2018

OCA — Wed, 07 Nov 2018 12:15:25 GMT

←Older revision		Revision as of 12:15, 7 November 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6eaq is ~~ON HOLD until Paper Publication~~	+	==Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc==
-		+	<StructureSection load='6eaq' size='340' side='right' caption='[[6eaq]], [[Resolution\|resolution]] 2.22Å' scene=''>
-	~~Authors~~: ~~Roberts~~, J.T., ~~Barb~~, A.W.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[6eaq]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EAQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6EAQ FirstGlance]. <br>
-	~~Description~~: ~~Glycosylated FCGR3B~~ / ~~CD16b~~ in ~~complex~~ with ~~afucosylated IgG1 Fc~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6eaq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6eaq OCA], [http://pdbe.org/6eaq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6eaq RCSB], [http://www.ebi.ac.uk/pdbsum/6eaq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6eaq ProSAT]</span></td></tr>
-	[[Category: Barb, A.W]]	+	</table>
-	[[Category: Roberts, J.T]]	+	== Function ==
		+	[[http://www.uniprot.org/uniprot/IGG1_HUMAN IGG1_HUMAN]] Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref> [[http://www.uniprot.org/uniprot/FCG3B_HUMAN FCG3B_HUMAN]] Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Barb, A W]]
		+	[[Category: Roberts, J T]]
		+	[[Category: Cd16b]]
		+	[[Category: Fcgr3b]]
		+	[[Category: Glycoprotein]]
		+	[[Category: Glycosylation]]
		+	[[Category: Igg1 fc]]
		+	[[Category: Immune system]]

OCA at 04:41, 22 August 2018

OCA — Wed, 22 Aug 2018 04:41:40 GMT

←Older revision		Revision as of 04:41, 22 August 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6eaq is ON HOLD	+	The entry 6eaq is ON HOLD until Paper Publication

	Authors: Roberts, J.T., Barb, A.W.		Authors: Roberts, J.T., Barb, A.W.

OCA: Protected "6eaq" [edit=sysop:move=sysop]

OCA — Wed, 15 Aug 2018 14:47:35 GMT

Protected "6eaq" [edit=sysop:move=sysop]

←Older revision

Revision as of 14:47, 15 August 2018

OCA: New page: '''Unreleased structure''' The entry 6eaq is ON HOLD Authors: Roberts, J.T., Barb, A.W. Description: Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc [[Category: Unrele...

OCA — Wed, 15 Aug 2018 14:47:33 GMT

New page: '''Unreleased structure''' The entry 6eaq is ON HOLD Authors: Roberts, J.T., Barb, A.W. Description: Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc [[Category: Unrele...

New page

'''Unreleased structure'''

The entry 6eaq is ON HOLD

Authors: Roberts, J.T., Barb, A.W.

Description: Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc
[[Category: Unreleased Structures]]
[[Category: Barb, A.W]]
[[Category: Roberts, J.T]]